Antitumor Polycyclic Acridines. Part 12. Physical and Biological Properties of 8,13-Diethyl-6-methylquino[4,3,2-kl]acridinium Iodide: A Lead Compound in Anticancer Drug Design

Oncology Research

Volumn 13, Issue 3, 2002, Pages 175-189

  Missailidis, Sotiris ^a,b   Stanslas, Johnson ^a,c   Modi, Chetna ^a   Ellis, Michael J ^a   Robins, R Adrian ^a   Laughton, Charles A ^a   Stevens, Malcolm F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

^c Universiti Putra Malaysia   (Malaysia)

Author keywords

Circular dichroism; DNA binding; Fluorescence; Polycyclic acridine derivatives; Spectrophotometric analysis; UV

Indexed keywords

8,13 DIETHYL 6 METHYLQUINO[4,3,2 KL]ACRIDINIUM IODIDE; ACRIDINE DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; PROTEIN P21; PROTEIN P53; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; 8,13 DIETHYL 6 METHYLQUINO(4,3,2 KL)ACRIDINIUM IODIDE; 8,13-DIETHYL-6-METHYLQUINO(4,3,2-KL)ACRIDINIUM IODIDE; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA; ENZYME INHIBITOR; HETERODUPLEX;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCULAR DICHROISM; DNA BINDING; DNA HELIX; DNA STRUCTURE; DRUG ANALYSIS; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORESCENCE; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY; STRUCTURE ANALYSIS; ULTRAVIOLET SPECTROSCOPY; BIOCHEMISTRY; CELL CULTURE; CELL CYCLE; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; SPECTROFLUOROMETRY; ULTRAVIOLET SPECTROPHOTOMETRY;

ACRIDINES; ANTINEOPLASTIC AGENTS; BIOCHEMISTRY; CELL CYCLE; CELL NUCLEUS; CIRCULAR DICHROISM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOPLASM; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; NEOPLASMS; NUCLEIC ACID HETERODUPLEXES; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037588730     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Albert, A. In: The acridines, 2nd ed.. London: Edward Arnold Ltd.; 1966.
2. Denny, W. A. In: Waring, M. J.; Ponder, B. A. J., eds. The search for new anticancer drugs. Dordrecht: Kluwer Academic Publishers; 1992:19.
3. Denny, W. A.; Baguley, B. C. New anticancer acridines. In: Neidle, S.; Waring, M. J., eds. Molecular aspects of anticancer drug-DNA interaction, 1st ed. London: Macmillan; 1994:270.
4. Arlin, Z. A. A special role for amsacrine in the treatment of acute leukemia. Cancer Invest. 7:607; 1989.
5. Harvey, V. J.; Hardy, J. R.; Smith, S.; Grove, W.; Baguley, B. C. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small-cell lung cancer. Eur. J. Cancer 27:1617; 1991.
6. Mcdonald, L. A.; Eldredge, G. S.; Barrows, L. R.; Ireland, C. M. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodites sp. ascidian: A mechanism for the apparent intercalator-induced inhibition of topoisomerase II. J. Med. Chem. 37:3819; 1994.
7. Hagan, D. J.; Giménez-Arnau, E.; Schwalbe, C. H.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 1. Synthesis of 7H-pyrido- and 8H-quino[4,3,2-kl]acridines by Graebe-Ullmann thermolysis of 9-(1,2,3-triazol-1-yl)acridines: Application of differential scanning calorimetry to predict optimum cyclisation conditions. J. Chem. Soc. Perkin Trans. I:2739; 1997.
8. Hagan, D. J.; Chan, D.; Schwalbe, C. H.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 3. A two-step conversion of 9-azidoacridine to 7H-pyrido[4,3,2-kl]acridines by Graebe-Ullmann thermolysis of substituted 9-(1,2,3-triazol-1-yl)acridines. J. Chem. Soc. Perkin Trans. I:915; 1998.
9. Julino, M.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 5. Synthesis of 7H-pyrido[4,3,2-kl]acridines with exploitable functionality in the pyridine ring. J. Chem. Soc. Perkin Trans. I:1677; 1998.
10. Stanslas, J.; Hagan, D. J.; Ellis, M. J.; Turner, C.; Carmichael, J.; Ward, W.; Hammonds, T. R.; Stevens, M. F. G. Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and penta-cyclic acridines. J. Med. Chem. 43:1563; 2000.
11. Giménez-Arnau, E.; Missailidis, S.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 2. Physico-chemical studies on the interactions between DNA and novel polycyclic acridine derivatives. Anti-Cancer Drug Design 13:125; 1998.
12. Giménez-Arnau, E.; Missailidis, S.; Stevens, M. F. G. Antitumour polycyclic acridines. Part 4. Physicochemical studies on the interactions between DNA and novel tetracyclic acridine derivatives. Anti-Cancer Drug Design 13:431; 1998.
13. Bostock-Smith, C. E.; Giménez-Amau, E.; Missailidis, S.; Laughton, C. A.; Stevens, M. F. G.; Searle, M. S. Molecular recognition between a new pentacyclic acridinium salt and DNA sequences investigated by optical spectroscopic techniques, proton nuclear magnetic resonance spectroscopy and molecular modeling. Biochemistry 38:6723; 1999.
14. Turner, C. The role of caspase-3 in drug induced apoptosis. Ph.D. thesis, University of Nottingham, Nottingham, UK; 2001.
15. Kohn, K. W. Beyond DNA cross-linking: History and prospects of DNA-targeted cancer treatment. Cancer Res. 56:5533; 1996.
16. Plum, G. E.; Pilch, D. S.; Singleton, S. F.; Breslauer, K. J. Nucleic-acid hybridization-triplex stability and energetics. Annu. Rev. Biophys. Biomol. Struct. 24:319; 1995.
17. Behe M. J. An overabundance of long oligopurine tracts occurs in the genome of simple and complex eukaryotes. Nucleic Acids Res. 23:689; 1965.
18. Frank-Kamenetskii, M. D.; Mirkin, S. M. Triplex DNA structures. Annu. Rev. Biochem. 64:65; 1995.
19. Sun, J. S.; Francois, J. C.; Montenay-Garestier, T.; Saison-Behmoaras, T.; Roig, V.; Chassignol, M.; Thoung, N. T.; Hélène, C. Sequence-specific intercalating agents-intercalation at specific sequences on duplex DNA via major groove recognition by oligonucleotide intercalator conjugates. Proc. Natl. Acad. Sci. USA 86:9198; 1989.
20. Latimer, L. J. P.; Payton, N.; Forsyth, G.; Lee, J. S. The binding of analogs of coralyne and related heterocyclics to DNA triplexes. Biochem. Cell. Biol. 73:11; 1995.
21. Cassidy, S. A.; Strekowski, L.; Fox, K. R. DNA sequence specificity of a naphthylquinone triple helix-binding ligand. Nucleic Acids Res. 24:4133; 1996.
22. Chandler, S. P.; Strekowski, L.; Wilson, W. D.; Fox, K. R. Foot-printing studies on ligands which stabilize DNA triplexes-effects on stringency within a parallel triple-helix. Biochemistry 34:7234; 1995.
23. Fox, K. R. Kinetic-studies on the formation of acridine-linked DNA triple helices. FEBS Lett. 357:312; 1995.
24. Cassidy, S. A.; Strekowski, L.; Wilson, W. D.; Fox, K. Effect of a tripler-binding ligand on parallel and antiparallel DNA triple helices using short unmodified and acridine-linked oligonucleotides. Biochemistry 33:15338; 1994.
25. Brown, P. M.; Drabble, A.; Fox, K. R. Effect of a triplex-binding ligand on triple helix formation at a site within a natural DNA fragment. Biochem. J. 314:427; 1996.
26. Mergny, J. L.; Duval-Valentin, G.; Nguen, C. H.; Perrouault, L.; Faucon, B.; Rougee, M.; Montenay-Garestier, T.; Bisangni, E.; Hélène, C. Triple helix specific ligands. Science 256:1681; 1992.
27. Silver, G. C.; Nguyen, C. H.; Boutorine, A. S.; Bisangi, E.; Montenay-Garestier, T.; Hélène, C. Conjugates of oligonucleotides with triplex-specific intercalating agents. Stabilization of triple-helical DNA in the promoter region of the gene for the alpha-subunit of interleukin 2 (IL-2R alpha). BioConj. Chem. 8:15; 1997.
28. Kim, N. W.; Piatyszek, M. A.; Prowse, K. R.; Harley, C. B.; West, M. D.; Ho, P. L. C.; Coviello, G. M.; Wright, W. E.; Weinrich, S. L.; Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011; 1994.
29. Hahn, W. C.; Stewart, S. A.; Brooks, M. W.; York, S. G.; Eaton, E.; Kurachi, A.; Beijerssbergen, R. L.; Knoll, J. H. M.; Mayerson, M.; Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5:1164; 1999.
30. Neidle, S.; Kelland, L. R. Telomerase as an anti-cancer target: Current status and future prospects. Anti-Cancer Drug Design 14:341; 1999.
31. Pitts, A. E.; Corey, D. R. The telomerase challenge-an unusual problem in drug discovery. Drug Discovery Today 4:155; 1999.
32. Kelland, L. R. Telomerase inhibitors: Targeting the vulnerable end of cancer? Anticancer Drugs 11:503; 2000.
33. Read, M.; Harrison, R. J.; Romagnoli, B.; Tanious, F. A.; Gowan, S. M.; Reszka, A. P.; Wilson, W. D.; Kelland, L. R.; Neidle, S. Structure-based design of selective and potent G-quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. USA 98:4844; 2001.
34. Gowan, S. M.; Heald, R.; Stevens, M. F. G.; Kelland, L. R. Potent inhibition of telomerase by small molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 60:981-988; 2001.
35. Heald, R. A.; Modi, C.; Cookson, J. C.; Hutchinson, I.; Laughton, C. A.; Gowan, S. M.; Kelland, L. R.; Stevens, M. F. G. Antitumor polycyclic acridines. 8. Synthesis and telomerase inhibitory activity of methylated pentacyclic acridinium salts. J. Med. Chem. 45:590; 2002.
36. Oszczapowicz, J.; Jaroszewska-Manaj, J.; Ciszak, E.; Gdaniec, M. A novel reaction of quinaldinium salts. Tetrahedron 44:6645; 1988.
37. Plouvier, B.; Houssin, R.; Helbecque, N.; Colson, P.; Houssier, C.; Henichart, J.-P.; Bailly, C. Influence of the methyl substituents of a thiazole-containing lexitropsin on the mode of binding to DNA. Anti-Cancer Drug Design I0:155; 1995.
38. S4) and its domains by circular dichroism. Mol. Microbiol. 24:653; 1997.
39. Ren, J.; Chaires, J. B. Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry 38:16067; 1999.
40. Jones, G. B.; Davey, C. L.; Jenkins, T. C.; Kamal, A.; Kneale, G.; Neidle, S.; Webster, G. D.; Thurston, D. E. The non-covalent interaction of pyrrolo [2,1-c][1,4] benzodiazepine-5,11-diones with DNA. Anti-Cancer Drug Design 5:249; 1990.
41. Mezces, L. M.; Marsh, K. L.; Fisher, L. M.; Rogers, M. P.; Austin, C. A. Complementation of temperature sensitive topoisomerase II mutations in S. cerevisiae by a human TOP2β construct allows study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother. Pharmacol. 39:367; 1997.
42. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 13:91; 1995.
43. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J.; Kohn, K. W.; Fojo, T.; Bates, S.; Rubenstein, V.; Anderson, N. L.; Buolamwini, J. K.; Van Osdol, W. W.; Monks, A.; Scuderio, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 275:343; 1997.
44. Wilson, W. R.; Baguley, B. C.; Wakelin, L. P. G.; Waring, M. J. Interaction of the antitumour drug m-AMSA (4-(9′ -acridinylamino)methanesulphon-m-anisidide) and related acridines with nucleic acids. Mol. Pharmacol. 20:404; 1981.
45. Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential anti-tumor agents. 34. Quantitative relationships between DNA-binding and molecular-structure for 9-anilinoacridines substituted in the anilino ring. J. Med. Chem. 24:170; 1981.
46. Denny, W. A.; Atwell, G. J.; Baguley, B. C. Potential anti-tumor agents. 39. Anilino ring geometry of amsacrine and derivatives - relationship to DNA-binding and anti-tumor activity. J. Med. Chem. 26:1625; 1983.
47. Lyng, R.; Rodger, A.; Norden, B. The CD of ligand-DNA systems. 1. Poly(dG-dC) B-DNA. Biopolymer 31:1709; 1991.
48. Lyng, R.; Rodger, A.; Norden, B. The CD of ligand-DNA systems. 2. Poly(dA-dT) B-DNA. Biopolymer 32:1201; 1992.
49. Norden, B.; Kubista, M.; Kurucsev, T. The linear dichroism spectroscopy of nucleic acids. Q. Rev. Biophys. 25:51; 1992.
50. Schipper, P. E.; Norden, B. Spectroscopic investigation of magnetic dipole allowed transitions through the magnetic transition moment. Chem. Phys. Lett. 67:99; 1979.
51. Norden, B.; Tjerneld, F. Structure of methylene-blue-DNA complexes studied by linear and circular dichroism spectroscopy. Biopolymers 21:1713; 1982.
52. Wirth, M.; Buchardt, O.; Koch, T.; Nielsen, P. E.; Norden, B. Interactions between DNA and mono-, bis-, tris-, tetrakis-, and hexakis(aminoacridines). A linear and circular dichroism, electric orientation relaxation, viscometry, and equilibrium study. J. Am. Chem. Soc. 110:932; 1988.
53. Houlbrook, S.; Addison, C. M.; Davies, S. L.; Carmichael, J.; Stratford, I. J.; Harris, A. L.; Hickson, I. D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer 72:1454; 1995.
54. Houlbrook, S.; Harris, A. L.; Carmichael, J.; Stratford, I. J. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res. 16:1603; 1996.
55. Hernandez, L.; Cholody, W. M.; Hudson, E. A.; Resau, J. H.; Pauly, G.; Michejda, C. J. Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Res. 55:2338; 1995.
56. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81:323; 1995.
57. Cho, Y.; Gorina, S.; Jeffrey, P. D.; Pavletich, N. R. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutation. Science 265:346; 1994.
58. Hachiya, M.; Chumakov, A.; Miller, C. W.; Akashi, M.; Said, J.; Koeffler, H. P. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res. 14:1853; 1994.
59. Harvey, M.; Vogel, H.; Bradley, A.; Bernstein, A.; Donehower, L. A. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305; 1995.
60. Dittmer, D.; Pati, S.; Zambetti, G.; Chu, S.; Teresky, A. K.; Moore, M.; Finlay, C.; Levine, A. J. Gain of function mutation in p53. Nat. Genet. 4:42; 1993.
61. Teixeira, C.; Reed, J. C.; Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:3902; 1995.
62. Sakura, C.; Sweeney, E. A.; Shirahama, T.; Igarashi, Y.; Hakomori, S.; Nakatani, H.; Tsujimoto, H.; Imanishi, T.; Ohgaki, M.; Ohyama, T.; Yamazaki, J. ; Hagiwara, A.; Yamaguchi, T.; Sawai, K.; Takahashi, T. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer 67:101; 1996.
63. Piche, A.; Grim, J.; Rancourt, C.; Navarro, J. G.; Reed, J. C.; Curiel, D. T. Modulation of bcl-2 single chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:2134; 1998.
64. Finlay, G. J.; Riou, J.-F.; Baguley, B. C. From amsacrine to DACA (N-[2-dimethylaminoethyl] acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer 32A:708; 1996.
65. Cooney, M.; Czernuszewicz, G.; Postel, E. H.; Flint, S. J.; Hogan, M. E. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 241:456; 1988.
66. Baran, N.; Lapidot, A.; Manor, H. Formation of DNA triplexes accounts for arrests of DNA-synthesis at d(TC)N and d(GA)N tracts. Proc. Natl. Acad. Sci. USA 88:507; 1991.
67. Dayn, A.; Samadashwily, G. M.; Mirkin, S. M. Intramolecular DNA triplexes-unusual sequence requirements and influence on DNA polymerisation. Proc. Natl. Acad. Sci. USA 89:11406; 1992.
68. Francois, J. C.; Saison-Behmoaras, T.; Thoung, N. T.; Hélène, C. Inhibition of restriction endonuclease cleavage via triple helix formation by homopyrimidine oligonucleotides. Biochemistry 28: 9617; 1989.
69. Maher, L. J.; Wold, B.; Dervan, P. B. Inhibition of DNA-binding proteins by oligonucleotide-directed triple helix formation. Science 245:725; 1989.